ArticlePharmacoEconomics2001
Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.
Article in PharmacoEconomics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 144 citations in OpenAlex.
- Forecast model for the evaluation of economic resources employed in the health care of patients with HIV infection.ClinicoEconomics and outcomes research : CEOR · 2012Article
- Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2010Article
- Economic costs to business of the HIV/AIDS epidemic.PharmacoEconomics · 2004Review
- The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2003Article
- The HAART side of resource allocation.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2003Article
- Review
- Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study.PharmacoEconomics · 2003Article
- The association of access to medical care with regular source of care and sociodemographic characteristics in patients with HIV and tuberculosis.Journal of the National Medical Association · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of highly active antiretroviral therapy (HAART), including protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors, for the treatment of HIV infection has led to a dramatic decline of morbidity and mortality. The acquisition costs of HAART are substantial. However, these costs are partially offset by reduced inpatient care for opportunistic infections and other AIDS-related diseases. Furthermore, job productivity in patients infected with HIV is increased under HAART. In developed countries with a low unemployment rate, the discounted value of savings caused by increased productivity in earlier years exceeds the discounted value of later increases in costs resulting from morbidity. Therefore, HAART represents a very efficient treatment strategy that leads to overall cost savings when taking a societal perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.